Triad to provide radiopharma products for Novation

Novation, a U.S. group purchasing organization serving the healthcare industry, has awarded Triad Isotopes with a contract to become one of its radiopharmaceutical suppliers.

Triad has been selected as a supplier of both high-energy and low-energy nuclear pharmacy products. The Novation contract is a five-year award to provide radiopharmaceutical products at negotiated prices to the VHA, UHC and Provista members.

Triad of Orlando, Fla., is one of three companies selected to provide low-energy products and one of four companies selected to serve high-energy customers for the period extending from July 2012 through June 2017.

Novation’s radiopharmaceutical distribution contract took effect on July 1.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.